Timos Papagatsias: EHA24 is expected to be one of the most exciting EHA conferences to-date!
Timos Papagatsias, shared a post on LinkedIn:
“EHA24 is fast approaching and is expected to be one of the most exciting EHA conferences to-date!
Use our detailed preview and planner to get a feel of what to expect at the event, not just on the purely medical front, but also on the impact of AI and machine learning is already having on the space!
Scientific advances in Hematology!
From innovative therapies for Aggressive B-cell Lymphoma and DLBCL to groundbreaking clinical trials in AML, the landscape of hematological treatments is evolving.
Highlights at EHA24 include:
– New targeted therapies for Lymphoma and promising clinical trial results for novel agents like menin inhibitor revenumib and olutasidenib in AML.
– Advances in treatment combinations for CLL, featuring sonrotoclax and lisocabtagene maraleucel and insights into platelet disorders and immune thrombocytopenia in children.
– Developments in Sickle Cell Disease with osivelotor trials and breakthroughs in Multiple Myeloma with CAR-T cell therapies.
– Updates in Myelofibrosis and Mastocytosis from the PATHFINDER study.
– New treatments and long-term data in CML, Bone Marrow Failure Syndromes, and PNH.
Artificial intelligence in Hematology:
– Risk Stratification and Prognosis: Random Forest models predicting 3-month survival in HLH with 79% AUC.
– Non-Invasive Assessments: High-accuracy hemoglobin measurement with Ridge Regression and LightGBM models.
– Molecular/Genetic Analysis: RNA-Seq based AI models classifying BCR ABL1-like BCP-ALL with up to 98% accuracy.
– Therapeutic Predictions: ML-driven risk stratification in DREAMM trials for MM treatment.
– Automated Diagnostics: Automated PBS analyzer significantly reducing evaluation time vs. traditional methods.
AI in Clinical Trials:
– Digital Twins: AI-derived cohorts showing ORR aligning with real-world data, enhancing clinical trial design.
– Clinical Applications: AI models predicting AML survival, aiding in patient risk stratification.
Stay tuned for more and like/share this post to see more like it!
See you in Madrid!!
Reach out to LucidQuest at [email protected] to find out more about what we do and how we can support your brand to thrive!”
Source: Timos Papagatsias/LinkedIn